Early research (Phase 1)Study completedNCT05829356
What this trial is testing
Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
Who this might be right for
Influenza Immunization
Sanofi Pasteur, a Sanofi Company 159